Titan Biotech Ltd
Incorporated in 1992, Titan Biotech
Ltd manufacturer and exporter of
the Biological products[1]
- Market Cap ₹ 889 Cr.
- Current Price ₹ 1,076
- High / Low ₹ 1,419 / 374
- Stock P/E 40.4
- Book Value ₹ 186
- Dividend Yield 0.18 %
- ROCE 16.9 %
- ROE 15.0 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 40 | 46 | 53 | 57 | 65 | 79 | 142 | 124 | 144 | 164 | 156 | 160 | |
| 36 | 42 | 47 | 50 | 56 | 66 | 96 | 92 | 114 | 130 | 131 | 134 | |
| Operating Profit | 4 | 4 | 5 | 7 | 9 | 13 | 46 | 31 | 30 | 34 | 25 | 26 |
| OPM % | 10% | 9% | 10% | 12% | 14% | 17% | 32% | 25% | 21% | 21% | 16% | 16% |
| 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 2 | 2 | 4 | 4 | |
| Interest | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 4 |
| Profit before tax | 2 | 3 | 3 | 4 | 6 | 10 | 43 | 29 | 28 | 32 | 24 | 25 |
| Tax % | 33% | 34% | 35% | 35% | 30% | 25% | 26% | 25% | 25% | 25% | 25% | |
| 2 | 2 | 2 | 3 | 4 | 8 | 32 | 22 | 25 | 25 | 22 | 22 | |
| EPS in Rs | 2.11 | 2.29 | 2.82 | 3.28 | 4.26 | 8.56 | 36.71 | 26.24 | 30.06 | 30.07 | 26.05 | 26.62 |
| Dividend Payout % | 36% | 33% | 27% | 23% | 0% | 12% | 4% | 6% | 6% | 7% | 8% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 15% |
| 3 Years: | 8% |
| TTM: | -7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 26% |
| 3 Years: | 0% |
| TTM: | -12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 43% |
| 5 Years: | 54% |
| 3 Years: | 60% |
| 1 Year: | 20% |
| Return on Equity | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 25% |
| 3 Years: | 20% |
| Last Year: | 15% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Reserves | 13 | 14 | 15 | 17 | 24 | 31 | 60 | 78 | 102 | 125 | 145 |
| 8 | 11 | 22 | 26 | 24 | 24 | 16 | 9 | 9 | 8 | 3 | |
| 5 | 7 | 7 | 7 | 9 | 13 | 16 | 13 | 16 | 15 | 19 | |
| Total Liabilities | 34 | 40 | 52 | 57 | 65 | 76 | 101 | 108 | 135 | 157 | 175 |
| 11 | 11 | 13 | 14 | 29 | 31 | 34 | 35 | 36 | 52 | 57 | |
| CWIP | 1 | 5 | 9 | 13 | 0 | 0 | 0 | 4 | 13 | 3 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 15 | 28 | 33 |
| 21 | 24 | 30 | 30 | 36 | 45 | 67 | 65 | 70 | 74 | 83 | |
| Total Assets | 34 | 40 | 52 | 57 | 65 | 76 | 101 | 108 | 135 | 157 | 175 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -2 | 5 | 0 | 2 | 5 | 6 | 19 | 22 | 21 | 21 | 20 | |
| -3 | -5 | -8 | -6 | -4 | -2 | -5 | -16 | -21 | -20 | -10 | |
| 3 | 2 | 9 | 0 | -0 | -4 | -11 | -4 | -2 | -3 | -8 | |
| Net Cash Flow | -2 | 2 | 1 | -3 | 1 | -0 | 4 | 2 | -2 | -2 | 2 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 58 | 47 | 44 | 49 | 52 | 54 | 46 | 48 | 53 | 42 | 44 |
| Inventory Days | 134 | 118 | 155 | 202 | 236 | 259 | 177 | 206 | 179 | 208 | 242 |
| Days Payable | 17 | 18 | 15 | 13 | 24 | 38 | 20 | 25 | 27 | 15 | 25 |
| Cash Conversion Cycle | 175 | 147 | 184 | 239 | 264 | 276 | 203 | 230 | 205 | 234 | 261 |
| Working Capital Days | 94 | 60 | 90 | 108 | 97 | 101 | 88 | 118 | 109 | 111 | 130 |
| ROCE % | 12% | 12% | 13% | 15% | 20% | 58% | 32% | 27% | 25% | 17% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Oct - Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September, 2025.
-
Disclosure Under Regulation 7(2) Of The SEBI (Prohibition Of Insider Trading) Regulations, 2015
29 Sep - Promoter Ravinder Gupta sold 4,000 shares on 29-Sep-2025 at ₹936.71 under trading plan.
-
Announcement under Regulation 30 (LODR)-Change in Management
27 Sep - AGM approved MDs reappointed Apr 1, 2026–Mar 31, 2031; increased WTD remunerations; independent director regularized.
-
Announcement under Regulation 30 (LODR)-Change in Management
27 Sep - Appointed Amit Anand as Secretarial Auditor for FY2025-26 to FY2029-30; approved Sept 26, 2025.
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
27 Sep - 33rd AGM Sep 26, 2025: adopted FY2024-25 financials, declared dividend, reappointed directors, approved loans, mortgages, remuneration and RPTs.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
TBL is an ISO 9001:2008 Certified & cGMP facilitated manufacturer & exporter of biological products used in the fields of Pharmaceutical, Nutraceutical, Food & Beverages, Biotechnology & Fermentation, Cosmetic, Veterinary & Animal
Feed, Agriculture Industries, Microbiology Culture Media & Plant Tissue Culture Media,
etc.